読み込み中
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
前日終値
$13.38
+$0.20 · +1.52%
日中の時刻はETです。市場データは遅延する場合があります。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日中レンジ
現在 $13.38
52週レンジ
現在 $13.38
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
49
まちまち
リスク
46
やや高いリスク
モメンタム
63
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
日中レンジ
現在 $13.38
52週レンジ
現在 $13.38
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 5000万 USD | — | — |
| 売上原価 | — | 25.8万 USD | — | — | — |
| 粗利益 | — | −25.8万 USD | 5000万 USD | — | — |
| 研究開発 | 5152.2万 USD | 3816.4万 USD | 2760.3万 USD | 1689.4万 USD | 2236万 USD |
| 販売・一般管理 | 1653.7万 USD | 1247.2万 USD | 632万 USD | 582.6万 USD | 628.7万 USD |
| 営業費用 | 6805.9万 USD | 5063.6万 USD | 6607.7万 USD | 2272万 USD | 2864.7万 USD |
| 受取利息 | 824.6万 USD | 890.5万 USD | 460.6万 USD | 76.1万 USD | 7.7万 USD |
| 支払利息 | — | — | 20.8万 USD | 38.8万 USD | 33.2万 USD |
| 減価償却費と償却費 | 32.3万 USD | 25.8万 USD | 19.5万 USD | 32.9万 USD | 32.5万 USD |
| 営業利益 | −6805.9万 USD | −5089.4万 USD | −1607.7万 USD | −2272万 USD | −2864.7万 USD |
| 純利益 | −5997.8万 USD | −4225.8万 USD | 2272万 USD | −2425.3万 USD | −2900.1万 USD |
会社概要が更新されました 2026年10月10日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1595.19万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM961.19万0.01%782.66億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF498万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Value ETFIWN333.93万0.02%138.48億 USD0.24%$210.87-0.04%
iShares Biotechnology ETFIBB305.23万0.03%102.79億 USD0.44%$206.49+3.00%
State Street SPDR S&P Pharmaceuticals ETFXPH294.91万0.65%4.62億 USD0.35%$64.65+1.60%
Vanguard Russell 2000 ETFVTWO251.11万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA210.66万0.01%217.28億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
